#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Cutaneous squamous cell carcinoma ( cSCC ) is the second most common type of cancer with an annual incidence of over one million globally .
3-1	17-26	Cutaneous	object[4]	new[4]	appos	3-6[0_4]
3-2	27-35	squamous	object[4]	new[4]	_	_
3-3	36-40	cell	place|object[4]	new|new[4]	coref	6-7
3-4	41-50	carcinoma	object[4]	new[4]	_	_
3-5	51-52	(	_	_	_	_
3-6	53-57	cSCC	object	giv	coref	3-9[6_0]
3-7	58-59	)	_	_	_	_
3-8	60-62	is	_	_	_	_
3-9	63-66	the	object[6]	giv[6]	coref	4-31[0_6]
3-10	67-73	second	object[6]	giv[6]	_	_
3-11	74-78	most	object[6]	giv[6]	_	_
3-12	79-85	common	object[6]	giv[6]	_	_
3-13	86-90	type	object[6]	giv[6]	_	_
3-14	91-93	of	object[6]	giv[6]	_	_
3-15	94-100	cancer	object[6]|abstract	giv[6]|new	coref	9-17
3-16	101-105	with	object[6]	giv[6]	_	_
3-17	106-108	an	object[6]|abstract[8]	giv[6]|new[8]	_	_
3-18	109-115	annual	object[6]|abstract[8]	giv[6]|new[8]	_	_
3-19	116-125	incidence	object[6]|abstract[8]	giv[6]|new[8]	_	_
3-20	126-128	of	object[6]|abstract[8]	giv[6]|new[8]	_	_
3-21	129-133	over	object[6]|abstract[8]	giv[6]|new[8]	_	_
3-22	134-137	one	object[6]|abstract[8]	giv[6]|new[8]	_	_
3-23	138-145	million	object[6]|abstract[8]	giv[6]|new[8]	_	_
3-24	146-154	globally	object[6]|abstract[8]	giv[6]|new[8]	_	_
3-25	155-156	.	_	_	_	_

#Text=Chronic ultraviolet ( UV ) exposure was suggested to be responsible for DNA damage of normal keratinocytes in the epidermis , which leads to the development of skin cancers including cSCC .
4-1	157-164	Chronic	abstract[9]	new[9]	appos	4-4[0_9]
4-2	165-176	ultraviolet	abstract[9]	new[9]	_	_
4-3	177-178	(	_	_	_	_
4-4	179-181	UV	abstract	giv	_	_
4-5	182-183	)	_	_	_	_
4-6	184-192	exposure	abstract	new	_	_
4-7	193-196	was	_	_	_	_
4-8	197-206	suggested	_	_	_	_
4-9	207-209	to	_	_	_	_
4-10	210-212	be	_	_	_	_
4-11	213-224	responsible	_	_	_	_
4-12	225-228	for	_	_	_	_
4-13	229-232	DNA	substance|abstract[13]	new|new[13]	_	_
4-14	233-239	damage	abstract[13]	new[13]	_	_
4-15	240-242	of	abstract[13]	new[13]	_	_
4-16	243-249	normal	abstract[13]|substance[14]	new[13]|new[14]	_	_
4-17	250-263	keratinocytes	abstract[13]|substance[14]	new[13]|new[14]	_	_
4-18	264-266	in	abstract[13]|substance[14]	new[13]|new[14]	_	_
4-19	267-270	the	abstract[13]|substance[14]|object[15]	new[13]|new[14]|new[15]	_	_
4-20	271-280	epidermis	abstract[13]|substance[14]|object[15]	new[13]|new[14]|new[15]	_	_
4-21	281-282	,	_	_	_	_
4-22	283-288	which	_	_	_	_
4-23	289-294	leads	_	_	_	_
4-24	295-297	to	_	_	_	_
4-25	298-301	the	event[16]	new[16]	_	_
4-26	302-313	development	event[16]	new[16]	_	_
4-27	314-316	of	event[16]	new[16]	_	_
4-28	317-321	skin	event[16]|object|abstract[18]	new[16]|new|new[18]	_	_
4-29	322-329	cancers	event[16]|abstract[18]	new[16]|new[18]	_	_
4-30	330-339	including	event[16]|abstract[18]	new[16]|new[18]	_	_
4-31	340-344	cSCC	event[16]|abstract[18]|abstract	new[16]|new[18]|giv	coref	20-20
4-32	345-346	.	_	_	_	_

#Text=However , the detailed underlying molecular mechanisms for this transition still need to be fully elucidated .
5-1	347-354	However	_	_	_	_
5-2	355-356	,	_	_	_	_
5-3	357-360	the	abstract[20]	new[20]	coref	9-3[51_20]
5-4	361-369	detailed	abstract[20]	new[20]	_	_
5-5	370-380	underlying	abstract[20]	new[20]	_	_
5-6	381-390	molecular	abstract[20]	new[20]	_	_
5-7	391-401	mechanisms	abstract[20]	new[20]	_	_
5-8	402-405	for	abstract[20]	new[20]	_	_
5-9	406-410	this	abstract[20]|event[21]	new[20]|new[21]	_	_
5-10	411-421	transition	abstract[20]|event[21]	new[20]|new[21]	_	_
5-11	422-427	still	_	_	_	_
5-12	428-432	need	_	_	_	_
5-13	433-435	to	_	_	_	_
5-14	436-438	be	_	_	_	_
5-15	439-444	fully	_	_	_	_
5-16	445-455	elucidated	_	_	_	_
5-17	456-457	.	_	_	_	_

#Text=Apoptosis is one type of programmed cell death , which is initiated by intrinsic or extrinsic signals and finely-tuned by many factors including BCL-2 family proteins .
6-1	458-467	Apoptosis	abstract	new	coref	6-3[23_0]
6-2	468-470	is	_	_	_	_
6-3	471-474	one	abstract[23]	giv[23]	coref	7-24[0_23]
6-4	475-479	type	abstract[23]	giv[23]	_	_
6-5	480-482	of	abstract[23]	giv[23]	_	_
6-6	483-493	programmed	abstract[23]|event[25]	giv[23]|new[25]	coref	8-3[40_25]
6-7	494-498	cell	abstract[23]|place|event[25]	giv[23]|giv|new[25]	coref	8-3
6-8	499-504	death	abstract[23]|event[25]	giv[23]|new[25]	_	_
6-9	505-506	,	_	_	_	_
6-10	507-512	which	_	_	_	_
6-11	513-515	is	_	_	_	_
6-12	516-525	initiated	_	_	_	_
6-13	526-528	by	_	_	_	_
6-14	529-538	intrinsic	abstract[26]	new[26]	_	_
6-15	539-541	or	abstract[26]	new[26]	_	_
6-16	542-551	extrinsic	abstract[26]	new[26]	_	_
6-17	552-559	signals	abstract[26]	new[26]	_	_
6-18	560-563	and	_	_	_	_
6-19	564-576	finely-tuned	_	_	_	_
6-20	577-579	by	_	_	_	_
6-21	580-584	many	abstract[27]	new[27]	coref	18-4[137_27]
6-22	585-592	factors	abstract[27]	new[27]	_	_
6-23	593-602	including	abstract[27]	new[27]	_	_
6-24	603-608	BCL-2	abstract[27]|substance[29]	new[27]|new[29]	coref	7-6[34_29]
6-25	609-615	family	abstract[27]|organization|substance[29]	new[27]|new|new[29]	coref	7-2
6-26	616-624	proteins	abstract[27]|substance[29]	new[27]|new[29]	_	_
6-27	625-626	.	_	_	_	_

#Text=BCL-2 family members , including both anti-apoptotic and pro-apoptotic BCL-2 family proteins , govern mitochondrial outer membrane permeabilization ( MOMP ) to regulate apoptosis .
7-1	627-632	BCL-2	person[31]	new[31]	coref	10-1[56_31]
7-2	633-639	family	organization|person[31]	giv|new[31]	coref	7-11
7-3	640-647	members	person[31]	new[31]	_	_
7-4	648-649	,	person[31]	new[31]	_	_
7-5	650-659	including	person[31]	new[31]	_	_
7-6	660-664	both	person[31]|substance[34]	new[31]|giv[34]	coref	14-10[98_34]
7-7	665-679	anti-apoptotic	person[31]|substance[34]	new[31]|giv[34]	_	_
7-8	680-683	and	person[31]|substance[34]	new[31]|giv[34]	_	_
7-9	684-697	pro-apoptotic	person[31]|substance[34]	new[31]|giv[34]	_	_
7-10	698-703	BCL-2	person[31]|abstract|substance[34]	new[31]|new|giv[34]	coref	10-4
7-11	704-710	family	person[31]|organization|substance[34]	new[31]|giv|giv[34]	coref	10-49[74_0]
7-12	711-719	proteins	person[31]|substance[34]	new[31]|giv[34]	_	_
7-13	720-721	,	_	_	_	_
7-14	722-728	govern	_	_	_	_
7-15	729-742	mitochondrial	_	_	_	_
7-16	743-748	outer	abstract[36]	new[36]	appos	7-20[0_36]
7-17	749-757	membrane	object|abstract[36]	new|new[36]	coref	17-34
7-18	758-774	permeabilization	abstract[36]	new[36]	_	_
7-19	775-776	(	_	_	_	_
7-20	777-781	MOMP	abstract	giv	coref	8-8
7-21	782-783	)	_	_	_	_
7-22	784-786	to	_	_	_	_
7-23	787-795	regulate	_	_	_	_
7-24	796-805	apoptosis	event	giv	coref	9-7
7-25	806-807	.	_	_	_	_

#Text=When apoptotic cell death program starts , MOMP releases cytochrome c to cytosol and activates caspase-family proteases for initiating apoptotic events .
8-1	808-812	When	_	_	_	_
8-2	813-822	apoptotic	event[41]	new[41]	_	_
8-3	823-827	cell	place|event[40]|event[41]	giv|giv[40]|new[41]	coref|coref|coref|coref	11-20[0_40]|15-11|11-20[0_40]|15-11
8-4	828-833	death	event[40]|event[41]	giv[40]|new[41]	_	_
8-5	834-841	program	event[41]	new[41]	_	_
8-6	842-848	starts	_	_	_	_
8-7	849-850	,	_	_	_	_
8-8	851-855	MOMP	event|event[43]|abstract[44]	giv|new[43]|new[44]	_	_
8-9	856-864	releases	event[43]|abstract[44]	new[43]|new[44]	_	_
8-10	865-875	cytochrome	abstract[44]	new[44]	_	_
8-11	876-877	c	abstract[44]|substance	new[44]|new	_	_
8-12	878-880	to	abstract[44]	new[44]	_	_
8-13	881-888	cytosol	abstract[44]|place	new[44]|new	_	_
8-14	889-892	and	_	_	_	_
8-15	893-902	activates	_	_	_	_
8-16	903-917	caspase-family	_	_	_	_
8-17	918-927	proteases	abstract	new	_	_
8-18	928-931	for	_	_	_	_
8-19	932-942	initiating	_	_	_	_
8-20	943-952	apoptotic	substance|event[49]	new|new[49]	_	_
8-21	953-959	events	event[49]	new[49]	_	_
8-22	960-961	.	_	_	_	_

#Text=Tumors develop effective mechanisms to resist apoptosis and thus become one of the hallmark features of cancer .
9-1	962-968	Tumors	object	new	coref	20-20[156_0]
9-2	969-976	develop	_	_	_	_
9-3	977-986	effective	abstract[51]	giv[51]	coref	22-3[165_51]
9-4	987-997	mechanisms	abstract[51]	giv[51]	_	_
9-5	998-1000	to	_	_	_	_
9-6	1001-1007	resist	_	_	_	_
9-7	1008-1017	apoptosis	abstract	giv	coref	21-14[163_0]
9-8	1018-1021	and	_	_	_	_
9-9	1022-1026	thus	_	_	_	_
9-10	1027-1033	become	_	_	_	_
9-11	1034-1037	one	abstract[53]	new[53]	_	_
9-12	1038-1040	of	abstract[53]	new[53]	_	_
9-13	1041-1044	the	abstract[53]|abstract[54]	new[53]|new[54]	_	_
9-14	1045-1053	hallmark	abstract[53]|abstract[54]	new[53]|new[54]	_	_
9-15	1054-1062	features	abstract[53]|abstract[54]	new[53]|new[54]	_	_
9-16	1063-1065	of	abstract[53]|abstract[54]	new[53]|new[54]	_	_
9-17	1066-1072	cancer	abstract[53]|abstract[54]|abstract	new[53]|new[54]|giv	coref	11-17
9-18	1073-1074	.	_	_	_	_

#Text=The lead member BCL-2 and its homologue BCL-XL ( BCL2L1 ) are featured by the presence of four conserved BH domains , three of which , BH1 , BH2 , and BH3 domains , are responsible for their antiapoptotic role mainly by interactions with other proapoptotic members of the BCL-2 family .
10-1	1075-1078	The	person[56]	giv[56]	ana	10-38[0_56]
10-2	1079-1083	lead	person[56]	giv[56]	_	_
10-3	1084-1090	member	person[56]	giv[56]	_	_
10-4	1091-1096	BCL-2	object	giv	ana	10-6
10-5	1097-1100	and	_	_	_	_
10-6	1101-1104	its	object|object[59]	giv|new[59]	coref|coref	24-6[0_59]|24-6[0_59]
10-7	1105-1114	homologue	object[59]	new[59]	_	_
10-8	1115-1121	BCL-XL	object[59]	new[59]	_	_
10-9	1122-1123	(	_	_	_	_
10-10	1124-1130	BCL2L1	abstract	new	_	_
10-11	1131-1132	)	_	_	_	_
10-12	1133-1136	are	_	_	_	_
10-13	1137-1145	featured	_	_	_	_
10-14	1146-1148	by	_	_	_	_
10-15	1149-1152	the	abstract[61]	new[61]	_	_
10-16	1153-1161	presence	abstract[61]	new[61]	_	_
10-17	1162-1164	of	abstract[61]	new[61]	_	_
10-18	1165-1169	four	abstract[61]|abstract[63]	new[61]|new[63]	_	_
10-19	1170-1179	conserved	abstract[61]|abstract[63]	new[61]|new[63]	_	_
10-20	1180-1182	BH	abstract[61]|person|abstract[63]	new[61]|new|new[63]	_	_
10-21	1183-1190	domains	abstract[61]|abstract[63]	new[61]|new[63]	_	_
10-22	1191-1192	,	abstract[61]	new[61]	_	_
10-23	1193-1198	three	abstract[61]|quantity	new[61]|new	_	_
10-24	1199-1201	of	abstract[61]	new[61]	_	_
10-25	1202-1207	which	abstract[61]|abstract[65]	new[61]|new[65]	_	_
10-26	1208-1209	,	abstract[61]|abstract[65]	new[61]|new[65]	_	_
10-27	1210-1213	BH1	abstract[61]|abstract[65]	new[61]|new[65]	_	_
10-28	1214-1215	,	abstract[61]	new[61]	_	_
10-29	1216-1219	BH2	abstract[61]|abstract	new[61]|new	_	_
10-30	1220-1221	,	abstract[61]	new[61]	_	_
10-31	1222-1225	and	abstract[61]	new[61]	_	_
10-32	1226-1229	BH3	abstract[61]|person|abstract[68]	new[61]|new|new[68]	_	_
10-33	1230-1237	domains	abstract[61]|abstract[68]	new[61]|new[68]	_	_
10-34	1238-1239	,	_	_	_	_
10-35	1240-1243	are	_	_	_	_
10-36	1244-1255	responsible	_	_	_	_
10-37	1256-1259	for	_	_	_	_
10-38	1260-1265	their	person|abstract[70]	giv|new[70]	coref|coref	10-45[72_0]|10-45[72_0]
10-39	1266-1279	antiapoptotic	abstract[70]	new[70]	_	_
10-40	1280-1284	role	abstract[70]	new[70]	_	_
10-41	1285-1291	mainly	_	_	_	_
10-42	1292-1294	by	_	_	_	_
10-43	1295-1307	interactions	abstract[71]	new[71]	_	_
10-44	1308-1312	with	abstract[71]	new[71]	_	_
10-45	1313-1318	other	abstract[71]|person[72]	new[71]|giv[72]	coref	11-5[77_72]
10-46	1319-1331	proapoptotic	abstract[71]|person[72]	new[71]|giv[72]	_	_
10-47	1332-1339	members	abstract[71]|person[72]	new[71]|giv[72]	_	_
10-48	1340-1342	of	abstract[71]|person[72]	new[71]|giv[72]	_	_
10-49	1343-1346	the	abstract[71]|person[72]|organization[74]	new[71]|giv[72]|giv[74]	coref	13-10[0_74]
10-50	1347-1352	BCL-2	abstract[71]|person[72]|person|organization[74]	new[71]|giv[72]|new|giv[74]	coref	11-6
10-51	1353-1359	family	abstract[71]|person[72]|organization[74]	new[71]|giv[72]|giv[74]	_	_
10-52	1360-1361	.	_	_	_	_

#Text=Inhibiting the activities of anti-apoptotic BCL-2 members by drugs or neutralizing by BH3 peptides to prime cancer cells to death has been regarded as effective therapeutic modalities .
11-1	1362-1372	Inhibiting	_	_	_	_
11-2	1373-1376	the	abstract[75]	new[75]	_	_
11-3	1377-1387	activities	abstract[75]	new[75]	_	_
11-4	1388-1390	of	abstract[75]	new[75]	_	_
11-5	1391-1405	anti-apoptotic	abstract[75]|person[77]	new[75]|giv[77]	coref	12-13[88_77]
11-6	1406-1411	BCL-2	abstract[75]|event|person[77]	new[75]|giv|giv[77]	coref	12-14
11-7	1412-1419	members	abstract[75]|person[77]	new[75]|giv[77]	_	_
11-8	1420-1422	by	abstract[75]|person[77]	new[75]|giv[77]	_	_
11-9	1423-1428	drugs	abstract[75]|person[77]|substance	new[75]|giv[77]|new	_	_
11-10	1429-1431	or	abstract[75]|person[77]	new[75]|giv[77]	_	_
11-11	1432-1444	neutralizing	abstract[75]|person[77]	new[75]|giv[77]	_	_
11-12	1445-1447	by	_	_	_	_
11-13	1448-1451	BH3	abstract|substance[80]	new|new[80]	coref|coref	16-1[110_80]|16-1[110_80]
11-14	1452-1460	peptides	substance[80]	new[80]	_	_
11-15	1461-1463	to	substance[80]	new[80]	_	_
11-16	1464-1469	prime	substance[80]|object[82]	new[80]|new[82]	coref	16-22[116_82]
11-17	1470-1476	cancer	substance[80]|abstract|object[82]	new[80]|giv|new[82]	coref	12-17
11-18	1477-1482	cells	substance[80]|object[82]	new[80]|new[82]	_	_
11-19	1483-1485	to	substance[80]|object[82]	new[80]|new[82]	_	_
11-20	1486-1491	death	substance[80]|object[82]|event	new[80]|new[82]|giv	coref	15-10[108_0]
11-21	1492-1495	has	_	_	_	_
11-22	1496-1500	been	_	_	_	_
11-23	1501-1509	regarded	_	_	_	_
11-24	1510-1512	as	_	_	_	_
11-25	1513-1522	effective	_	_	_	_
11-26	1523-1534	therapeutic	_	_	_	_
11-27	1535-1545	modalities	_	_	_	_
11-28	1546-1547	.	_	_	_	_

#Text=In another way , transcriptionally or post-transcriptionally repressing the expression levels of anti-apoptotic BCL-2 members in cancer is also promising .
12-1	1548-1550	In	_	_	_	_
12-2	1551-1558	another	abstract[84]	new[84]	_	_
12-3	1559-1562	way	abstract[84]	new[84]	_	_
12-4	1563-1564	,	_	_	_	_
12-5	1565-1582	transcriptionally	_	_	_	_
12-6	1583-1585	or	_	_	_	_
12-7	1586-1608	post-transcriptionally	_	_	_	_
12-8	1609-1619	repressing	_	_	_	_
12-9	1620-1623	the	abstract[86]	new[86]	_	_
12-10	1624-1634	expression	abstract|abstract[86]	new|new[86]	coref	13-6[91_0]
12-11	1635-1641	levels	abstract[86]	new[86]	_	_
12-12	1642-1644	of	abstract[86]	new[86]	_	_
12-13	1645-1659	anti-apoptotic	abstract[86]|person[88]	new[86]|giv[88]	coref	13-9[94_88]
12-14	1660-1665	BCL-2	abstract[86]|event|person[88]	new[86]|giv|giv[88]	coref	13-9
12-15	1666-1673	members	abstract[86]|person[88]	new[86]|giv[88]	_	_
12-16	1674-1676	in	abstract[86]|person[88]	new[86]|giv[88]	_	_
12-17	1677-1683	cancer	abstract[86]|person[88]|abstract	new[86]|giv[88]|giv	_	_
12-18	1684-1686	is	_	_	_	_
12-19	1687-1691	also	_	_	_	_
12-20	1692-1701	promising	_	_	_	_
12-21	1702-1703	.	_	_	_	_

#Text=However , the mechanism regulating the expression of BCL-2 family members still remain unclear .
13-1	1704-1711	However	_	_	_	_
13-2	1712-1713	,	_	_	_	_
13-3	1714-1717	the	abstract[90]	new[90]	_	_
13-4	1718-1727	mechanism	abstract[90]	new[90]	_	_
13-5	1728-1738	regulating	_	_	_	_
13-6	1739-1742	the	abstract[91]	giv[91]	_	_
13-7	1743-1753	expression	abstract[91]	giv[91]	_	_
13-8	1754-1756	of	abstract[91]	giv[91]	_	_
13-9	1757-1762	BCL-2	abstract[91]|event|person[94]	giv[91]|giv|giv[94]	_	_
13-10	1763-1769	family	abstract[91]|organization|person[94]	giv[91]|giv|giv[94]	_	_
13-11	1770-1777	members	abstract[91]|person[94]	giv[91]|giv[94]	_	_
13-12	1778-1783	still	_	_	_	_
13-13	1784-1790	remain	_	_	_	_
13-14	1791-1798	unclear	_	_	_	_
13-15	1799-1800	.	_	_	_	_

#Text=Autophagy is an evolutionarily-conserved catabolic process , during which “ useless ” proteins and damaged organelles are sequestrated into autophagosomes and fused with lysosomes to form autolysosomes for bulk degradation of embedded components .
14-1	1801-1810	Autophagy	abstract	new	coref	14-3[97_0]
14-2	1811-1813	is	_	_	_	_
14-3	1814-1816	an	abstract[97]	giv[97]	coref	15-2[106_97]
14-4	1817-1841	evolutionarily-conserved	abstract[97]	giv[97]	_	_
14-5	1842-1851	catabolic	person|abstract[97]	new|giv[97]	_	_
14-6	1852-1859	process	abstract[97]	giv[97]	_	_
14-7	1860-1861	,	_	_	_	_
14-8	1862-1868	during	_	_	_	_
14-9	1869-1874	which	_	_	_	_
14-10	1875-1876	“	substance[98]	giv[98]	_	_
14-11	1877-1884	useless	substance[98]	giv[98]	_	_
14-12	1885-1886	”	substance[98]	giv[98]	_	_
14-13	1887-1895	proteins	substance[98]	giv[98]	_	_
14-14	1896-1899	and	substance[98]	giv[98]	_	_
14-15	1900-1907	damaged	substance[98]|object[99]	giv[98]|new[99]	_	_
14-16	1908-1918	organelles	substance[98]|object[99]	giv[98]|new[99]	_	_
14-17	1919-1922	are	_	_	_	_
14-18	1923-1935	sequestrated	_	_	_	_
14-19	1936-1940	into	_	_	_	_
14-20	1941-1955	autophagosomes	object	new	_	_
14-21	1956-1959	and	_	_	_	_
14-22	1960-1965	fused	_	_	_	_
14-23	1966-1970	with	_	_	_	_
14-24	1971-1980	lysosomes	object	new	_	_
14-25	1981-1983	to	_	_	_	_
14-26	1984-1988	form	_	_	_	_
14-27	1989-2002	autolysosomes	place	new	_	_
14-28	2003-2006	for	_	_	_	_
14-29	2007-2011	bulk	abstract[103]	new[103]	coref	17-41[135_103]
14-30	2012-2023	degradation	abstract[103]	new[103]	_	_
14-31	2024-2026	of	abstract[103]	new[103]	_	_
14-32	2027-2035	embedded	abstract[103]|abstract[104]	new[103]|new[104]	coref	17-43[0_104]
14-33	2036-2046	components	abstract[103]|abstract[104]	new[103]|new[104]	_	_
14-34	2047-2048	.	_	_	_	_

#Text=Except the dysregulated autophagic process defined as type II programmed cell death , autophagy is generally regarded as protective cellular process .
15-1	2049-2055	Except	_	_	_	_
15-2	2056-2059	the	abstract[106]	giv[106]	coref	15-14[0_106]
15-3	2060-2072	dysregulated	abstract[106]	giv[106]	_	_
15-4	2073-2083	autophagic	abstract|abstract[106]	new|giv[106]	_	_
15-5	2084-2091	process	abstract[106]	giv[106]	_	_
15-6	2092-2099	defined	_	_	_	_
15-7	2100-2102	as	_	_	_	_
15-8	2103-2107	type	_	_	_	_
15-9	2108-2110	II	_	_	_	_
15-10	2111-2121	programmed	event[108]	giv[108]	_	_
15-11	2122-2126	cell	place|event[108]	giv|giv[108]	_	_
15-12	2127-2132	death	event[108]	giv[108]	_	_
15-13	2133-2134	,	_	_	_	_
15-14	2135-2144	autophagy	event	giv	coref	17-26
15-15	2145-2147	is	_	_	_	_
15-16	2148-2157	generally	_	_	_	_
15-17	2158-2166	regarded	_	_	_	_
15-18	2167-2169	as	_	_	_	_
15-19	2170-2180	protective	_	_	_	_
15-20	2181-2189	cellular	_	_	_	_
15-21	2190-2197	process	_	_	_	_
15-22	2198-2199	.	_	_	_	_

#Text=The recycled peptides , nucleotides and lipids together with the energy are critical to the maintenance of cellular homeostasis and support tumor cells to survive under stressful environment .
16-1	2200-2203	The	substance[110]	giv[110]	_	_
16-2	2204-2212	recycled	substance[110]	giv[110]	_	_
16-3	2213-2221	peptides	substance[110]	giv[110]	_	_
16-4	2222-2223	,	substance[110]	giv[110]	_	_
16-5	2224-2235	nucleotides	substance[110]|plant	giv[110]|new	_	_
16-6	2236-2239	and	substance[110]	giv[110]	_	_
16-7	2240-2246	lipids	substance[110]|substance[112]	giv[110]|new[112]	_	_
16-8	2247-2255	together	substance[110]|substance[112]|substance[113]	giv[110]|new[112]|new[113]	_	_
16-9	2256-2260	with	substance[110]|substance[112]|substance[113]	giv[110]|new[112]|new[113]	_	_
16-10	2261-2264	the	substance[110]|substance[112]|substance[113]	giv[110]|new[112]|new[113]	_	_
16-11	2265-2271	energy	substance[110]|substance[112]|substance[113]	giv[110]|new[112]|new[113]	_	_
16-12	2272-2275	are	_	_	_	_
16-13	2276-2284	critical	_	_	_	_
16-14	2285-2287	to	_	_	_	_
16-15	2288-2291	the	event[114]	new[114]	_	_
16-16	2292-2303	maintenance	event[114]	new[114]	_	_
16-17	2304-2306	of	event[114]	new[114]	_	_
16-18	2307-2315	cellular	event[114]|abstract[115]	new[114]|new[115]	_	_
16-19	2316-2327	homeostasis	event[114]|abstract[115]	new[114]|new[115]	_	_
16-20	2328-2331	and	_	_	_	_
16-21	2332-2339	support	_	_	_	_
16-22	2340-2345	tumor	object[116]	giv[116]	coref	20-23[0_116]
16-23	2346-2351	cells	object[116]	giv[116]	_	_
16-24	2352-2354	to	_	_	_	_
16-25	2355-2362	survive	_	_	_	_
16-26	2363-2368	under	_	_	_	_
16-27	2369-2378	stressful	abstract[117]	new[117]	_	_
16-28	2379-2390	environment	abstract[117]	new[117]	_	_
16-29	2391-2392	.	_	_	_	_

#Text=Autophagy-related genes ( ATGs ) , including ULK1 ( ATG1 ) , ATG3 , and ATG12 etc. , are involved in the distinct stages of autophagy : initiation , autophagosome nucleation , autophagosome membrane expansion , fusion with lysosome and the intravesicular components degradation .
17-1	2393-2410	Autophagy-related	abstract[118]	new[118]	appos	17-4[0_118]
17-2	2411-2416	genes	abstract[118]	new[118]	_	_
17-3	2417-2418	(	_	_	_	_
17-4	2419-2423	ATGs	abstract	giv	coref	18-10[139_0]
17-5	2424-2425	)	_	_	_	_
17-6	2426-2427	,	_	_	_	_
17-7	2428-2437	including	_	_	_	_
17-8	2438-2442	ULK1	abstract	new	appos	17-10
17-9	2443-2444	(	_	_	_	_
17-10	2445-2449	ATG1	abstract	giv	coref	24-14
17-11	2450-2451	)	_	_	_	_
17-12	2452-2453	,	_	_	_	_
17-13	2454-2458	ATG3	abstract	new	coref	24-16
17-14	2459-2460	,	_	_	_	_
17-15	2461-2464	and	_	_	_	_
17-16	2465-2470	ATG12	object	new	coref	24-19
17-17	2471-2475	etc.	_	_	_	_
17-18	2476-2477	,	_	_	_	_
17-19	2478-2481	are	_	_	_	_
17-20	2482-2490	involved	_	_	_	_
17-21	2491-2493	in	_	_	_	_
17-22	2494-2497	the	abstract[124]	new[124]	_	_
17-23	2498-2506	distinct	abstract[124]	new[124]	_	_
17-24	2507-2513	stages	abstract[124]	new[124]	_	_
17-25	2514-2516	of	abstract[124]	new[124]	_	_
17-26	2517-2526	autophagy	abstract[124]|event	new[124]|giv	coref	24-23
17-27	2527-2528	:	abstract[124]	new[124]	_	_
17-28	2529-2539	initiation	abstract[124]|event	new[124]|new	_	_
17-29	2540-2541	,	abstract[124]	new[124]	_	_
17-30	2542-2555	autophagosome	abstract[124]|abstract|event[128]	new[124]|new|new[128]	coref|coref	17-33|17-33
17-31	2556-2566	nucleation	abstract[124]|event[128]	new[124]|new[128]	_	_
17-32	2567-2568	,	abstract[124]	new[124]	_	_
17-33	2569-2582	autophagosome	abstract[124]|abstract|event[131]	new[124]|giv|new[131]	_	_
17-34	2583-2591	membrane	abstract[124]|object|event[131]	new[124]|giv|new[131]	_	_
17-35	2592-2601	expansion	abstract[124]|event[131]	new[124]|new[131]	_	_
17-36	2602-2603	,	abstract[124]	new[124]	_	_
17-37	2604-2610	fusion	abstract[124]|event[132]	new[124]|new[132]	_	_
17-38	2611-2615	with	abstract[124]|event[132]	new[124]|new[132]	_	_
17-39	2616-2624	lysosome	abstract[124]|event[132]|object	new[124]|new[132]|new	_	_
17-40	2625-2628	and	abstract[124]	new[124]	_	_
17-41	2629-2632	the	abstract[124]|abstract[135]	new[124]|giv[135]	_	_
17-42	2633-2647	intravesicular	abstract[124]|abstract[135]	new[124]|giv[135]	_	_
17-43	2648-2658	components	abstract[124]|abstract|abstract[135]	new[124]|giv|giv[135]	_	_
17-44	2659-2670	degradation	abstract[124]|abstract[135]	new[124]|giv[135]	_	_
17-45	2671-2672	.	_	_	_	_

#Text=Signaling pathways or critical factors are involved in regulating ATG genes , including Class III PI3-kinase complex I , mTORC I complex , mTORC II complex and Beclin1 et al. .
18-1	2673-2682	Signaling	_	_	_	_
18-2	2683-2691	pathways	place	new	_	_
18-3	2692-2694	or	_	_	_	_
18-4	2695-2703	critical	abstract[137]	giv[137]	_	_
18-5	2704-2711	factors	abstract[137]	giv[137]	_	_
18-6	2712-2715	are	_	_	_	_
18-7	2716-2724	involved	_	_	_	_
18-8	2725-2727	in	_	_	_	_
18-9	2728-2738	regulating	_	_	_	_
18-10	2739-2742	ATG	abstract|abstract[139]	new|giv[139]	coref|coref|coref|coref	19-8|19-7[148_139]|19-8|19-7[148_139]
18-11	2743-2748	genes	abstract[139]	giv[139]	_	_
18-12	2749-2750	,	abstract[139]	giv[139]	_	_
18-13	2751-2760	including	abstract[139]	giv[139]	_	_
18-14	2761-2766	Class	abstract[139]|abstract[140]	giv[139]|new[140]	_	_
18-15	2767-2770	III	abstract[139]|abstract[140]	giv[139]|new[140]	_	_
18-16	2771-2781	PI3-kinase	abstract[139]|abstract[140]|abstract	giv[139]|new[140]|new	_	_
18-17	2782-2789	complex	abstract[139]|abstract[140]	giv[139]|new[140]	_	_
18-18	2790-2791	I	abstract[139]|person	giv[139]|acc	_	_
18-19	2792-2793	,	abstract[139]	giv[139]	_	_
18-20	2794-2799	mTORC	abstract[139]|abstract	giv[139]|new	coref	18-24[145_0]
18-21	2800-2801	I	person	acc	_	_
18-22	2802-2809	complex	_	_	_	_
18-23	2810-2811	,	_	_	_	_
18-24	2812-2817	mTORC	abstract[145]	giv[145]	_	_
18-25	2818-2820	II	abstract[145]	giv[145]	_	_
18-26	2821-2828	complex	abstract[145]	giv[145]	_	_
18-27	2829-2832	and	abstract[145]	giv[145]	_	_
18-28	2833-2840	Beclin1	abstract[145]	giv[145]	_	_
18-29	2841-2843	et	abstract[145]	giv[145]	_	_
18-30	2844-2847	al.	abstract[145]	giv[145]	_	_
18-31	2848-2849	.	_	_	_	_

#Text=However , the transcriptional regulation of the ATG genes is not fully explored .
19-1	2850-2857	However	_	_	_	_
19-2	2858-2859	,	_	_	_	_
19-3	2860-2863	the	abstract[146]	new[146]	_	_
19-4	2864-2879	transcriptional	abstract[146]	new[146]	_	_
19-5	2880-2890	regulation	abstract[146]	new[146]	_	_
19-6	2891-2893	of	abstract[146]	new[146]	_	_
19-7	2894-2897	the	abstract[146]|abstract[148]	new[146]|giv[148]	coref	24-11[181_148]
19-8	2898-2901	ATG	abstract[146]|abstract|abstract[148]	new[146]|giv|giv[148]	coref	24-11
19-9	2902-2907	genes	abstract[146]|abstract[148]	new[146]|giv[148]	_	_
19-10	2908-2910	is	_	_	_	_
19-11	2911-2914	not	_	_	_	_
19-12	2915-2920	fully	_	_	_	_
19-13	2921-2929	explored	_	_	_	_
19-14	2930-2931	.	_	_	_	_

#Text=In our previous study , Homeobox A9 ( HOXA9 ) was significantly downregulated and identified as tumor suppressor in cSCC tumors and cells .
20-1	2932-2934	In	_	_	_	_
20-2	2935-2938	our	person|abstract[150]	acc|new[150]	coref|ana|coref|ana	23-2[168_150]|23-5|23-2[168_150]|23-5
20-3	2939-2947	previous	abstract[150]	new[150]	_	_
20-4	2948-2953	study	abstract[150]	new[150]	_	_
20-5	2954-2955	,	_	_	_	_
20-6	2956-2964	Homeobox	place|abstract[152]	new|new[152]	appos|appos	20-9[0_152]|20-9[0_152]
20-7	2965-2967	A9	abstract[152]	new[152]	_	_
20-8	2968-2969	(	_	_	_	_
20-9	2970-2975	HOXA9	abstract	giv	coref	21-1
20-10	2976-2977	)	_	_	_	_
20-11	2978-2981	was	_	_	_	_
20-12	2982-2995	significantly	_	_	_	_
20-13	2996-3009	downregulated	_	_	_	_
20-14	3010-3013	and	_	_	_	_
20-15	3014-3024	identified	_	_	_	_
20-16	3025-3027	as	_	_	_	_
20-17	3028-3033	tumor	abstract	new	coref	25-15
20-18	3034-3044	suppressor	_	_	_	_
20-19	3045-3047	in	_	_	_	_
20-20	3048-3052	cSCC	place|object[156]	giv|giv[156]	coref|coref	24-2|24-2
20-21	3053-3059	tumors	object[156]	giv[156]	_	_
20-22	3060-3063	and	object[156]	giv[156]	_	_
20-23	3064-3069	cells	object[156]|object	giv[156]|giv	coref	21-16[164_0]
20-24	3070-3071	.	_	_	_	_

#Text=HOXA9 functions in repressing the proliferation , migration and invasiveness , while promoting apoptosis of cSCC cells .
21-1	3072-3077	HOXA9	abstract|abstract[159]	giv|new[159]	coref|coref	22-7|22-7
21-2	3078-3087	functions	abstract[159]	new[159]	_	_
21-3	3088-3090	in	_	_	_	_
21-4	3091-3101	repressing	_	_	_	_
21-5	3102-3105	the	event[160]	new[160]	_	_
21-6	3106-3119	proliferation	event[160]	new[160]	_	_
21-7	3120-3121	,	_	_	_	_
21-8	3122-3131	migration	abstract	new	_	_
21-9	3132-3135	and	_	_	_	_
21-10	3136-3148	invasiveness	event	new	_	_
21-11	3149-3150	,	_	_	_	_
21-12	3151-3156	while	_	_	_	_
21-13	3157-3166	promoting	_	_	_	_
21-14	3167-3176	apoptosis	event[163]	giv[163]	coref	22-9[0_163]
21-15	3177-3179	of	event[163]	giv[163]	_	_
21-16	3180-3184	cSCC	event[163]|object[164]	giv[163]|giv[164]	_	_
21-17	3185-3190	cells	event[163]|object[164]	giv[163]|giv[164]	_	_
21-18	3191-3192	.	_	_	_	_

#Text=However , the mechanisms about how HOXA9 regulate apoptosis has not been explored and remain to be elucidated .
22-1	3193-3200	However	_	_	_	_
22-2	3201-3202	,	_	_	_	_
22-3	3203-3206	the	abstract[165]	giv[165]	_	_
22-4	3207-3217	mechanisms	abstract[165]	giv[165]	_	_
22-5	3218-3223	about	abstract[165]	giv[165]	_	_
22-6	3224-3227	how	abstract[165]	giv[165]	_	_
22-7	3228-3233	HOXA9	abstract	giv	coref	23-18
22-8	3234-3242	regulate	_	_	_	_
22-9	3243-3252	apoptosis	event	giv	coref	24-9
22-10	3253-3256	has	_	_	_	_
22-11	3257-3260	not	_	_	_	_
22-12	3261-3265	been	_	_	_	_
22-13	3266-3274	explored	_	_	_	_
22-14	3275-3278	and	_	_	_	_
22-15	3279-3285	remain	_	_	_	_
22-16	3286-3288	to	_	_	_	_
22-17	3289-3291	be	_	_	_	_
22-18	3292-3302	elucidated	_	_	_	_
22-19	3303-3304	.	_	_	_	_

#Text=In this study , we found RELA ( p65 subunit of NF-κB ) is transcriptionally repressed by HOXA9 .
23-1	3305-3307	In	_	_	_	_
23-2	3308-3312	this	abstract[168]	giv[168]	coref	25-1[188_168]
23-3	3313-3318	study	abstract[168]	giv[168]	_	_
23-4	3319-3320	,	_	_	_	_
23-5	3321-3323	we	person	giv	ana	25-1
23-6	3324-3329	found	_	_	_	_
23-7	3330-3334	RELA	abstract	new	coref	24-4
23-8	3335-3336	(	_	_	_	_
23-9	3337-3340	p65	abstract|quantity[172]	new|new[172]	_	_
23-10	3341-3348	subunit	quantity[172]	new[172]	_	_
23-11	3349-3351	of	quantity[172]	new[172]	_	_
23-12	3352-3357	NF-κB	quantity[172]|abstract	new[172]|new	_	_
23-13	3358-3359	)	_	_	_	_
23-14	3360-3362	is	_	_	_	_
23-15	3363-3380	transcriptionally	_	_	_	_
23-16	3381-3390	repressed	_	_	_	_
23-17	3391-3393	by	_	_	_	_
23-18	3394-3399	HOXA9	abstract	giv	_	_
23-19	3400-3401	.	_	_	_	_

#Text=In cSCC , RELA transactivates BCL-XL to antagonize apoptosis and ATG genes ( ULK1 , ATG3 , and ATG12 ) to promote autophagy .
24-1	3402-3404	In	_	_	_	_
24-2	3405-3409	cSCC	place	giv	coref	25-18
24-3	3410-3411	,	_	_	_	_
24-4	3412-3416	RELA	abstract	giv	_	_
24-5	3417-3431	transactivates	_	_	_	_
24-6	3432-3438	BCL-XL	object	giv	_	_
24-7	3439-3441	to	_	_	_	_
24-8	3442-3452	antagonize	_	_	_	_
24-9	3453-3462	apoptosis	event|abstract[179]	giv|new[179]	coref|coref|coref|coref	25-8[191_0]|25-8[192_179]|25-8[191_0]|25-8[192_179]
24-10	3463-3466	and	abstract[179]	new[179]	_	_
24-11	3467-3470	ATG	abstract[179]|abstract|abstract[181]	new[179]|giv|giv[181]	appos|appos	24-14[183_181]|24-14[183_181]
24-12	3471-3476	genes	abstract[179]|abstract[181]	new[179]|giv[181]	_	_
24-13	3477-3478	(	_	_	_	_
24-14	3479-3483	ULK1	place|abstract[183]	giv|giv[183]	_	_
24-15	3484-3485	,	abstract[183]	giv[183]	_	_
24-16	3486-3490	ATG3	abstract[183]|abstract	giv[183]|giv	_	_
24-17	3491-3492	,	abstract[183]	giv[183]	_	_
24-18	3493-3496	and	abstract[183]	giv[183]	_	_
24-19	3497-3502	ATG12	abstract[183]|abstract	giv[183]|giv	_	_
24-20	3503-3504	)	_	_	_	_
24-21	3505-3507	to	_	_	_	_
24-22	3508-3515	promote	_	_	_	_
24-23	3516-3525	autophagy	abstract	giv	coref	25-12
24-24	3526-3527	.	_	_	_	_

#Text=Our study highlights a HOXA9-NF-κB axis regulates both the apoptosis and autophagy to promote tumor development in cSCC , which may suggest novel intervention targets for cSCC therapy .
25-1	3528-3531	Our	person|abstract[188]	giv|giv[188]	_	_
25-2	3532-3537	study	abstract[188]	giv[188]	_	_
25-3	3538-3548	highlights	_	_	_	_
25-4	3549-3550	a	abstract[190]	new[190]	_	_
25-5	3551-3562	HOXA9-NF-κB	object|abstract[190]	new|new[190]	_	_
25-6	3563-3567	axis	abstract[190]	new[190]	_	_
25-7	3568-3577	regulates	_	_	_	_
25-8	3578-3582	both	event[191]|abstract[192]	giv[191]|giv[192]	_	_
25-9	3583-3586	the	event[191]|abstract[192]	giv[191]|giv[192]	_	_
25-10	3587-3596	apoptosis	event[191]|abstract[192]	giv[191]|giv[192]	_	_
25-11	3597-3600	and	abstract[192]	giv[192]	_	_
25-12	3601-3610	autophagy	abstract[192]|event	giv[192]|giv	_	_
25-13	3611-3613	to	_	_	_	_
25-14	3614-3621	promote	_	_	_	_
25-15	3622-3627	tumor	abstract|event[195]	giv|new[195]	_	_
25-16	3628-3639	development	event[195]	new[195]	_	_
25-17	3640-3642	in	event[195]	new[195]	_	_
25-18	3643-3647	cSCC	event[195]|organization	new[195]|giv	coref	25-27
25-19	3648-3649	,	_	_	_	_
25-20	3650-3655	which	_	_	_	_
25-21	3656-3659	may	_	_	_	_
25-22	3660-3667	suggest	_	_	_	_
25-23	3668-3673	novel	abstract[198]	new[198]	_	_
25-24	3674-3686	intervention	event|abstract[198]	new|new[198]	_	_
25-25	3687-3694	targets	abstract[198]	new[198]	_	_
25-26	3695-3698	for	abstract[198]	new[198]	_	_
25-27	3699-3703	cSCC	abstract[198]|abstract|abstract[200]	new[198]|giv|new[200]	_	_
25-28	3704-3711	therapy	abstract[198]|abstract[200]	new[198]|new[200]	_	_
25-29	3712-3713	.	_	_	_	_
